Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MindBio TherapeuticsFRA:WF60 37 EV-to-FCF is -2.54 as of Aug. 28, 2026. GuruFocus rates FRA:WF60 with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 321 Biotechnology companies, MindBio Therapeutics ranks worse than 311526.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MindBio Therapeutics's Enterprise Value is €2.42 Mil.
MindBio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.95 Mil. Therefore, MindBio Therapeutics's EV-to-FCF for today is -2.54.
The historical rank and industry rank for MindBio Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:WF60'
s EV-to-FCF Range Over the Past 10 Years
Min: -94.94 Med: -18.9 Max: -2.52
Current: -2.52
During the past 5 years, the highest EV-to-FCF of MindBio Therapeutics was -2.52. The lowest was -94.94. And the median was -18.90.
FRA:WF60's EV-to-FCF is ranked worse than 100% of 321
companies
in the Biotechnology industry
Industry Median: 17.48
vs FRA:WF60: -2.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MindBio Therapeutics's PE Ratio (TTM) for today is calculated as:
MindBio Therapeutics's share price for today is €0.134.
MindBio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MindBio Therapeutics EV-to-FCF Related Terms
MindBio Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for MindBio Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:WF60 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, MindBio Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindBio Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MindBio Therapeutics's EV-to-FCF falls into.
MindBio Therapeutics's current Enterprise Value is €2.42 Mil.
MindBio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindBio Therapeutics (FRA:WF60) has a EV-to-FCF of -2.54 as of Aug. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MindBio Therapeutics and its competitors. According to the industry distribution chart, MindBio Therapeutics ranks #999999 out of 321 companies in the Biotechnology industry.
Is MindBio Therapeutics' EV-to-FCF too high?
MindBio Therapeutics' current EV-to-FCF is -2.54. Based on the distribution chart, MindBio Therapeutics ranks #999999 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindBio Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does MindBio Therapeutics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindBio Therapeutics ranks #999999 out of 321 companies for EV-to-FCF. This places MindBio Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 17.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.48, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MindBio Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindBio Therapeutics's current EV-to-FCF is -2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindBio Therapeutics stock overvalued right now?
MindBio Therapeutics (FRA:WF60) has a current EV-to-FCF of -2.54. The current EV-to-FCF is -2.54. MindBio Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MindBio Therapeutics (FRA:WF60), the current EV-to-FCF is -2.54 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the company's activities take place in Australia.
37GF Score
Get the complete analysis for FRA:WF60
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:WF60 has been successfully added to your 
